Hormonal
Dulaglutide 1.5 mg reduces systolic blood pressure (SBP) and pulse pressure in patients with type 2 diabetes, with the majority of this reduction (64% for SBP, 86% for pulse pressure) being independent of weight loss.
If you have Type 2 Diabetes, taking dulaglutide (1.5 mg weekly) can lower your systolic blood pressure by about 2.6 mmHg after 6 months. Crucially, most of this benefit comes from the drug's direct effect on your blood vessels and nervous system, not just from losing weight. This means you may see blood pressure improvements even if your weight remains stable.
While up to one third of the effect of dulaglutide 1.5 mg on SBP and pulse pressure was due to weight reduction, the majority was independent of weight.
Why this rating
Meta-analysis of multiple randomized, placebo-controlled trials (n=6) with consistent results.
Source
Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes
Keith C. Ferdinand et al. · Cardiovascular Diabetology · 2023
DOI 10.1186/s12933-023-01775-x
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →